DATA TDM

  • Research type

    Research Study

  • Full title

    Analysis of Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment to Assess the Potential Role of Therapeutic Drug Monitoring in UK Infection Management (DATA TDM study)

  • IRAS ID

    306987

  • Contact name

    Alison Holmes

  • Contact email

    alison.holmes@imperial.ac.uk

  • Sponsor organisation

    Imperial College London

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    To address the challenge of antimicrobial resistance (AMR), it is imperative that the current finite pool of antimicrobial agents is optimised, to maximise therapeutic success, limit the risk of drug toxicity, whilst minimising emergence of resistance.

    Outside the critical care setting, it is not known how many patients are receiving optimal drug concentrations for the treatment of infection. This study aims to assess whether antimicrobial targets are being achieved in these individuals, and explore how clinical co-variates and outcomes might relate to this. Furthermore, it aims to identify priority groups and/or drugs where there are gaps in dose-optimisation research, and develop hypotheses which can be tested in interventional studies.

    Eligible participants will be enrolled and observed during their management for infection at Imperial College Hospital NHS Trust (ICHNT). After providing informed written consent, their clinical data will be collected from electronic healthcare records, and they will provide samples which will undergo drug concentration analysis.

  • REC name

    London - Brighton & Sussex Research Ethics Committee

  • REC reference

    22/LO/0063

  • Date of REC Opinion

    16 May 2022

  • REC opinion

    Further Information Favourable Opinion